The loss of expression of the transcription factor GATA3 in breast tumors has been linked to aggressive tumor development and poor patient survival. In the present work, we address potential roles for GATA3 in breast tumor lung metastasis and progression. Using an aggressive breast cancer cell line, which metastasizes specifically to the lung, we show that GATA3 expression results in reduced tumor outgrowth in the mammary fat pad and lower lung metastatic burden in nude mice. Specifically, GATA3 expression inhibits breast cancer cell expansion inside the lung parenchyma. This phenotype correlates with the ability of GATA3 to negatively regulate the expression of several genes that promote breast cancer lung metastasis (ID1/-3, KRTHB1, LY6E and RARRES3). Conversely, the expression of genes encoding known inhibitors of lung metastasis (DLC1 (deleted in liver cancer 1) and PAEP (progestagen-associated endometrial protein)) is upregulated by GATA3. These data correlate with microarray data from human breast cancer patients, showing a strong correlation between high GATA3 expression and absence of metastases specifically to the lungs. We conclude that GATA3 inhibits primary breast tumor outgrowth and reduces lung metastatic burden by regulating key genes involved in metastatic breast tumor progression.
Introduction
Yearly, breast cancer accounts for 26% of the new cancer cases in women, making it the most prevalent malignancy in females (Jemal et al., 2008) . The 5-year survival rate for patients with metastatic breast cancer is below 30% (Gupta and Massague, 2006; Jemal et al., 2008) . Mortality associated with breast cancer is indeed largely the result of tumor metastasis to distant organs, thus identifying the molecular pathways of tumor cell dissemination as critical targets of breast cancer treatment.
Metastatic breast cancer shows organ tropism, and most frequently metastasizes to the bones and the lungs. Metastasis to the skeleton is associated with considerable morbidity; however, metastasis to soft tissue sites (lungs, liver or brain) is associated with a faster clinical progression and mortality (Solomayer et al., 2000) . This organ tropism reflects distinct molecular profiles of the seeding breast cancer cells, with specific genetic programs favoring colonization and outgrowth in the bones, whereas others enable metastatic cells to establish in the lungs (Kang et al., 2003; Minn et al., 2005) . In general, the metastatic process is composed of several steps that begin in the primary tumor. Tumor cells must dissociate from the solid tumor and enter the blood or lymph flow, allowing dissemination throughout the organism. After extravasation, tumor cells must survive within a novel microenvironment, induce local angiogenesis and maintain a high proliferative capacity for the formation of a successful metastatic lesion (Johnston and Swanton, 2006) . Not surprisingly, each successive step in the metastatic cascade requires the expression of different genetic programs. A specific gene signature that facilitates tumor escape and extravasation has been identified (COX2 (cyclooxygenase 2), epiregulin, MMP-1 and -2 (matrix metalloproteinases 1 and 2)) (Gupta et al., 2007a) , whereas the transcriptional repressors ID1 and -3 are crucial for breast cancer cell outgrowth in the lung parenchyma (Gupta et al., 2007b) .
The GATA family of transcription factors plays crucial roles in organ development and lineage specification (Patient and McGhee, 2002) . Among them, GATA3 is crucial for Th2 lymphoid cell lineage specification in the immune system (Murphy, 2005) and for normal urogenital morphogenesis (Lim et al., 2000; Grote et al., 2006) . Furthermore, GATA3 plays an essential role in mammary gland development. Specifically, GATA3 is required for the outgrowth of the ductal tree, specification and differentiation of the luminal cell lineage, and maturation and differentiation of the lobuloalveolar units within the mature mammary gland (Asselin-Labat et al., 2006; Kouros-Mehr et al.,
2006
). In accordance with the role of GATA3 as a differentiation factor in the luminal cell lineage, overexpression of GATA3 in a pluripotent breast cancer model system leads to formation of non-aggressive lowgrade tumors (Kouros-Mehr et al., 2008a) . The effects of GATA3 expression in this model system included an impaired capacity for dissemination owing to the induction of a luminal cell differentiation program, as assessed by increased expression of luminal cell differentiation markers, such as a/b-caseins and estrogen receptor-a (ER). Of note, several studies have found a strong positive correlation between GATA3 and ER expression in breast cancer samples (Sorlie et al., 2001; van't Veer et al., 2002; Oh et al., 2006) , and ER has consequently been implicated as a direct and reciprocal target gene of GATA3 (Usary et al., 2004; Kouros-Mehr et al., 2006; Eeckhoute et al., 2007) .
Here, we show that GATA3 carries the capacity to inhibit primary breast tumor outgrowth and metastasis to the lungs. We find that GATA3 does not affect the ability of the breast cancer cells to extravasate into the lung parenchyma, but rather inhibits secondary growth after tumor cell colonization in the lungs. This process is mediated by a GATA3-regulated genetic program, which does not include ER, but rather consists of the repression of ID1 and ID3 and the regulation of other metastasis-associated genes. Interestingly, the effect of GATA3 on tumor growth was independent of cell differentiation. Together, these results shed new light on the role of GATA3 in breast cancer progression.
Results
High GATA3 expression is associated with long-term survival and a reduced probability of developing lung metastasis in a cohort of breast cancer patients Several gene expression studies associate GATA3 expression with the clinical progression of breast cancer, with high GATA3 levels in the primary tumor being favorable, whereas low or absent GATA3 expression is associated with poor patient prognosis (Sorlie et al., 2001; van de Vijver et al., 2002; van't Veer et al., 2002; Ma et al., 2003; Mehra et al., 2005; Wang et al., 2005; Ivshina et al., 2006; Desmedt et al., 2007) . As breast cancer mortality is primarily associated with the development of metastases (Johnston and Swanton, 2006) , we hypothesized that GATA3 may affect the metastatic process. To address this, we first assessed the expression levels of GATA3 in a clinical data set derived from a microarray experiment testing 99 breast cancer samples (Minn et al., 2005) . This data set provides information about gene expression levels, relapse-free survival time and metastatic sites at time of relapse for 82 of the patients. An analysis of GATA3 expression in primary tumors in relationship to sites of relapse revealed a striking association between high GATA3 expression and the absence of relapse, specifically to the lung (Figure 1a ; Po0.001, w 2 ). In contrast, GATA3 expression levels did not discriminate between patients with or without bone involvement (Figure 1b) . Hence, high GATA3 expression is strongly associated with the absence of lung metastasis in breast cancer patients.
GATA3 expression inhibits breast tumor outgrowth and spontaneous lung metastasis
To test the hypothesis that GATA3 can negatively regulate the ability of breast cancer cells to metastasize to the lung, we overexpressed GATA3 in the highly aggressive LM2-4175 (LM2) cell line. These cells, derived from MDA-MB-231, have been selected to form spontaneous lung metastasis in approximately 50% of recipient athymic nude (nu/nu) mice after injection in the mammary fat pad and express green fluorescent protein and firefly luciferase to allow monitoring by fluorescence and bioluminescence (Minn et al., 2005) . Of note, the LM2 cells express significantly lower levels of GATA3 than the parental MDA-MB-231 strain ( Supplementary Figure 1) , which is in accordance with the negative correlation between GATA3 expression and lung metastasis (Figure 1a ). Upon orthotopic injection in the mammary fat pad, 100% of LM2 cells transduced with an empty vector (LM2-EV) developed into palpable tumors within 7 days (Figure 2a ). In ). In addition to a delay in tumor onset, LM2-GATA3 cells showed a significant reduction in tumor outgrowth after mammary fat pad injection when compared with control LM2-EV cells (Figure 2b , mean tumor size at 31 days; 190 mm 3 (GATA3) vs 512 mm 3 (EV), P ¼ 0.0059, t-test, N ¼ 15). The experiment was carried out thrice with identical results. To verify that these results were obtained at physiological expression levels of GATA3, we compared the expression of GATA3 in the LM2-derived tumors with the expression in a normal breast cell line as well as in nine breast cancer cell lines. LM2-GATA3 tumors were found to express median levels of GATA3 (Supplementary Figure 3) .
Histological analysis of the tumors using hematoxylin and eosin staining revealed the presence of large coalescing areas of necrotic cell death at the periphery of LM2-GATA3 tumors (Figure 3b ), which is in marked contrast with LM2-EV tumors ( Figure 3a) . Overall, 35% of the total LM2-GATA3 tumor volume was necrotic, representing a significant increase in necrosis over the control cells (Po0.05, N ¼ 3) (Figure 3e ). The non-necrotic areas of the tumors appeared otherwise similar and were composed of densely populated sheets of cancer cells supported by a fine fibrovascular stroma. To determine whether reduced tumor growth was additionally associated with impaired proliferation, we determined the mitotic index of GATA3 and EV tumors by Ki67 immunostaining (Figures 3c-d, f ). This experiment revealed a 30% overall reduction of proliferation index in the non-necrotic areas of GATA3-expressing tumors (Po0.01, t-test, N ¼ 5) (Figure 3f ), which is in line with other studies of the role of GATA3 in epithelial cells (Grote et al., 2006; Kouros-Mehr et al., 2006) . Molecular analysis of angiogenesis in the non-necrotic areas using the endothelial marker, CD31, revealed no significant changes (not shown); however, a complete absence of vasculature in the necrotic areas was noted (not shown). Staining for apoptosis by terminal deoxynucleotidyl transferase dUTP nick end labeling failed to reveal any significant difference between both tumor types (not shown). As GATA3 and ER were shown to be part of a transcriptional network (Eeckhoute et al., 2007) , the expression of the ER gene (ESR1) was determined by reverse transcriptase (RT)-PCR in LM2-GATA3 and LM2-EV tumors ( Figure 3g ). This analysis revealed no changes in ESR1 expression levels. Importantly, the GATA3-transduced tumors retained GATA3 expression throughout the experiment (Figure 3h ).
Owing to the strong correlation between high GATA3 expression and lung-metastatic-free survival of breast cancer patients (Figure 1a ), we next determined whether animals carrying primary orthotopic tumors developed spontaneous metastatic lesions to the lungs. To allow spontaneous lung metastases to form, animals were killed when the primary tumor had reached a size of 1500 mm 3 . At the experimental end point three of eight animals carrying control cells and four of nine animals carrying GATA3-expressing cells presented with solitary tumor cells or minor (1-5 cells) lesions, as identified by green fluorescent protein immunofluorescence staining (Figures 4a-c) , which is in line with the known spontaneous metastatic capacity of LM2 cells (Minn et al., 2005) .
Of note, because of the reduced growth rate of primary GATA3-expressing tumors, the metastatic burden of GATA3-expressing primary tumors was assessed after an average time of 51 days, whereas control tumors reached 1500 mm 3 after 38 days, raising the possibility that GATA3 expression, in fact, delays metastatic spread to the lung.
GATA3 inhibits metastatic tumor outgrowth in the lungs, but does not affect extravasation to the lung parenchyma To gain further insight into the inhibitory effect of GATA3 on lung metastasis, we carried out intravenous injection of LM2-EV and LM2-GATA3 cells, and monitored the colonization and tumor outgrowth in the lungs. Interestingly, bioluminescence analysis carried out on day 10 showed a similar level of lung colonization in both LM2-EV and LM2-GATA3-injected animals ( Figure 5a ). This implies that GATA3 does not negatively affect the ability of breast cancer cells to extravasate from the blood stream and colonize the lung parenchyma. However, continued monitoring of xenograft progression for 70 days revealed a strong reduction in the outgrowth capacity of the lesions (Figures 5a-c) (MANOVA (multivariate analysis of variance), P ¼ 0.006). Hence, inhibition of secondary tumor outgrowth, rather than extravasation and colonization, are affected by GATA3 expression during the metastatic process.
GATA3 regulates metastasis-associated genes
To investigate the underlying molecular alterations invoked by GATA3 in LM2 breast cancer cells, we carried out comparative microarray analysis of LM2-EV and LM2-GATA3 primary tumors. Interestingly, the 30 most differentially regulated genes (Supplementary  Tables 1 and 2 ) included several genes related to breast cancer metastasis and malignancy (Goodison et al., 2005; Minn et al., 2005; Buess et al., 2007; Gupta et al., 2007b; Hautala et al., 2008) . The genes upregulated in GATA3-overexpressing cells included inhibitors of breast cancer growth and metastasis, such as PAEP (progestagenassociated endometrial protein) (Glycodelin) and DLC1 (deleted in liver cancer 1), whereas the prometastatic genes, ID1, ID3, LY6E, KRTHB1 and RARRES3, as well as the interferon-response genes, MX1, OAS1, G1P3 and IFI44L, were found to be downregulated in the presence of high GATA3 expression. To validate our microarray data, we carried out quantitative RT-PCR on RNA extracts from GATA3 and EV-LM2 tumors, as well as RNA from GATA3-expressing MDA-MB-453 breast cancer luminal cells or from MDA-MB-453 cells in which GATA3 has been knocked down by RNA interference (supplementary Figure 4) . Significantly, all of the above mentioned genes were reciprocally regulated in both experiments, in accordance with the results observed in microarray analysis (Figures 6a-d ). As several of the genes related to breast cancer progression harbors putative GATA3 binding sites, we next carried out chromatin immunoprecipitation analysis to verify whether GATA3 acts directly on these regulatory regions. Of the putative sites tested, a site at À216 bp in the promoter of IFI44L showed the highest enrichment (3.73-fold, Supplementary table 3). Taken together, these results show that several genes related to breast cancer metastasis and progression are part of transcriptional program acting downstream of GATA3.
As GATA3 functions as a differentiation factor in the mammary gland (Asselin-Labat et al., 2006; Kouros-Mehr et al., 2006 , 2008a , 2008b , we additionally examined our microarray data for the expression of mammary epithelium differentiation marker genes, namely casein-a/b/k, lactalbumin and carbonic anhydrase-3 and -6. None of these genes were significantly affected by GATA3 expression (Supplementary Table 4) , suggesting that GATA3 can inhibit breast cancer outgrowth independently of the initiation of a luminal cell differentiation program.
Discussion
Several studies have established a link between low or absent GATA3 expression in breast cancer and poor disease prognosis (Sorlie et al., 2001; van Desmedt et al., 2007) . A meta-analysis has additionally suggested that GATA3 expression levels independently hold more prognostic value than classic markers such as ER status (Mehra et al., 2005) . However, even though these studies are based upon large and clinically relevant patient samples, the conclusions drawn from them are correlative by nature rather than causal and little experimental data on the role of GATA3 in breast cancer is presently available. One study addressing the role of murine GATA3 in a mouse model of mammary gland tumorigenesis has recently been reported (Kouros-Mehr et al., 2008a, b) . Interestingly, this study found that overexpression of GATA3 in transplanted mouse mammary gland tumors resulted in large cystic tumors with a decreased capacity to disseminate (Kouros-Mehr et al., 2008a) . In the present study, we used a different experimental model that unveils other properties of GATA3 in mammary gland tumorigenesis. Our data identifies a causative role for GATA3 in preventing breast tumor and lung metastasis outgrowth, and provides novel insights into the transcriptional program downstream of GATA3 in breast cancer cells.
GATA3 in breast tumor metastasis to the lung
Our analysis of public cDNA microarray data (Minn et al., 2005) revealed that high GATA3 expression in the primary tumor of breast cancer patients is associated with a specific lack of metastasis to the lung in a 10-year follow-up period. The experimental validation of this observation using a model of aggressive lung metastasis confirmed the capacity of GATA3 to suppress lung metastasis outgrowth. These results are in line with published work showing a correlation between high GATA3 expression and reduced metastatic burden (Mehra et al., 2005) , as well as experimental evidence that GATA3 prevents breast tumor dissemination (Kouros-Mehr et al., 2008a) . Importantly, our results provide additional information regarding the mechanisms through which GATA3 negatively regulates breast tumor metastasis. In their study, Kouros-Mehr et al. (2008a) , come to the conclusion that GATA3 acts primarily by promoting mammary cell differentiation, as evidenced by the gain of luminal cell differentiation markers in GATA3-overexpressing tumors. In our experiments, however, the suppression of lung metastasis by GATA3 expression was not associated with the upregulation of luminal cell differentiation markers, showing an additional cellular function of GATA3 in preventing metastasis formation. Interestingly, tail vein injection of GATA3-expressing cells additionally revealed that tumor cell extravasation and colonization of the lung parenchyma are not significantly affected by GATA3 expression. Instead, metastasis outgrowth after cell engraftment is strongly reduced.
At the molecular level, it was revealing to identify genes associated with breast tumor lung metastasis among the GATA3-regulated genes. Notably, the genes, ID1 and ID3, LY6E, KRTHB1 and RARRES3, were repressed in cells expressing GATA3. All of these genes have been recognized as part of a gene expression signature predictive of metastatic tropism to the lungs (Minn et al., 2005) . Particularly, ID1 and ID3, were shown to facilitate secondary outgrowth of breast tumors metastases in the lungs (Gupta et al., 2007b) , which is in agreement with the role of GATA3 identified here. Of note, DLC1, which inhibits lung metastasis of breast cancer cells (Goodison et al., 2005) and PAEP (glycodelin), which inhibits breast cancer growth (Hautala et al., 2008) , were among the genes upregulated by GATA3. Hence, the combined repression of ID1/3, LY6E, KRTHB1 and RARRES3 and induction of DLC1 and PAEP in response to GATA3 overexpression may play a significant role in preventing lung metastasis. Although our use of reciprocal strategies validates these genes as genetic targets of GATA3, the modest enrichment found by chromatin immunoprecipitation suggests that these genes may not represent direct transcriptional targets of GATA3.
GATA3 in tumor growth
Another interesting observation is the significant inhibition of both primary and metastatic tumor outgrowth by GATA3. In primary tumors, we could identify a moderate reduction in the proliferation index of GATA3-expressing tumors that could partly account for the observed differences in mammary tumor size. This result is consistent with other reports showing that the loss of GATA3 in epithelial cells results in an increase in proliferation (Grote et al., 2006; KourosMehr et al., 2006) . However, it is unclear whether or not GATA3 has a direct effect on cell cycle progression. Arguing against this possibility is the fact that we did not identify any cell cycle regulator genes downstream of GATA3 in our microarray analysis of primary xenograft tumors, and the fact that GATA3 overexpression did not alter cell proliferation in vitro (data not shown). Significantly, however, GATA3-expressing xenografts harbored large areas of necrosis, not found in control tumors, which may also explain the reduction in tumor growth. Of note, these necrotic areas were devoid of vasculature and were mostly located at the tumor periphery instead of the more typical central necrosis observed in large tumors. As necrosis is likely the result of impaired nutrient supply, energy use or waste removal, these observations suggest that GATA3- expression may exert an effect on tumor metabolism, resulting in an overall reduction of tumor size increase over time.
GATA3 as a marker of breast cancer progression GATA3 and ER are part of a positive regulatory loop (Eeckhoute et al., 2007) and the loss of GATA3 expression during breast cancer progression is concordantly associated with the downregulation of ER, a classic hallmark of tumor progression and poor prognosis (Parikh et al., 2005; Oh et al., 2006; Voduc et al., 2008) . Whether or not GATA3 expression holds prognostic value independently of ER expression is still a matter of debate, as contradictory results have been obtained regarding this issue (Mehra et al., 2005; Voduc et al., 2008) . In the light of this, it is important to note that the anti-metastatic activity of GATA3 that we report here was not accompanied by alterations of ER expression levels, suggesting that GATA3 does not exert its anti-metastatic effect through ER activation. However, GATA3 expression leads to several genetic changes, such as an upregulation of PAEP/glycodelin, which is lost in late-stage breast cancer in a profile that parallels that of GATA3 (Jeschke et al., 2005; Shabani et al., 2005; Kouros-Mehr et al., 2008a) .
Another remarkable aspect of our results is the strong repressive effect of GATA3 on MX1 and OAS1, two genes involved in an interferon response signature associated with breast cancer metastasis and poor prognosis (Buess et al., 2007) . Two additional interferon response genes, namely G1P3 and IFI44L, were also found among the most repressed GATA3-target genes. Importantly, the downregulation of these interferonresponse genes was observed both in vivo and in vitro, and are derived from a human microarray ruling out the artifactual detection of host inflammatory response to xenograft tumors. Instead, these results suggest that the expression of GATA3 in tumor cells may intrinsically temper their interferon response. The precise role of this response in relation to GATA3 activity in breast cancer cells remains to be determined.
Although these observations does not directly address the validity of GATA3 as an independent prognostic marker, they do reveal an independent role for GATA3 in inhibition of breast tumor as well as lung metastasis growth, and identify several genes involved in breast cancer progression as genetic targets of GATA3. Together, this supports the potential use of GATA3 expression levels as prognostic tool, as well as the idea of an ER-independent role for GATA3 in breast cancer biology.
Materials and methods
Generation of mammary fat pad tumors and metastatic spread Female nude (nu/nu) CD1 mice (6-8 weeks of age) were obtained from Charles River Laboratories (Saint-Constant, QC, Canada). One million cells in 1:1 phosphate-buffered saline (PBS)/Matrigel (BD-Bioscience, Mississauga, ON, Canada) were injected in the right abdominal fat pad followed by tumor size measurements commencing on the seventh day after injection. Tumor size was measured using a vernier caliper and tumor volume was calculated according to the formula v ¼ pLW2/6, where 'L' is length and 'W' is width of the tumor. Experimental metastasis to the lungs was induced by injecting 200 000 cells in 200 ml of PBS in the tail vein of nu/ nu CD1 females. Real-time bioluminescence-based observation of metastatic growth was conducted by injecting firefly potassium salt D-Luciferin (Caliper Life Sciences, Hopkinton, MA, USA) to a final concentration of 75 mg/g body weight and monitoring light emission in a Xenogen IVIS Imaging System 100 (Xenogen, Hopkinton, MA, USA). All procedures were blinded to minimize experimental bias. All experimental animal work was approved by the local institutional Animal Ethics Committee.
Histology
Histological analysis of primary and metastatic tumors was carried out according to standard procedures. Primary tumors were harvested at 300 mm 3 to minimize size-related necrosis associated with the model. For spontaneous metastasis experiments, the primary tumor was allowed to reach 1500 mm 3 , at which point the animals were killed and the lungs and primary tumors isolated for histological analysis. Staining for Ki67 was carried out on five tumors from each experimental condition. Individual tumor value represents the average of six independent imaging fields.
Cell culture and genetic engineering of breast cancer cell lines
The LM2 4175 cells were grown in high glucose Dulbecco's modified Eagle's medium (Wisent, Saint-Jean-Baptiste de Rouville, QC, Canada) supplemented with 10% fetal bovine serum (Wisent) and 1% HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (Wisent). Retroviral infections of LM2-4175 cells were carried out with the retroviral expression vector pBabe using HEK-293T cells as packaging cells. Human GATA3 cDNA in pBabe was generously provided by Dr Perou (The University of North Carolina at Chapel Hill, NC, USA). Short hairpin RNA interference of GATA3 in MDA-MB-453 cells were done by lentivirus-mediated introduction of clone NM_002051.1-1231s1c1 (short hairpin sequence: 5 0 -CCG GCA TCC AGA CCA GAA ACC GAA ACT CGA GTT TCG GTT TCT GGT CTG GAT GTT TTT-3 0 ) from the MISSION shRNA library (Sigma, Oakville, Canada). All selections were carried out with Puromycin at a concentration of 1 mg/ml.
Immunoblotting and immunohistochemistry
Immunoblotting on whole cell lysates separated on a sodium dodecyl sulfate polyacrylamide gel electrophoresis gel was carried out as described (Ni et al., 2005) using an anti-GATA3 rabbit polyclonal antibody (ab11964, Abcam, Cambridge, MA, USA) or a mouse monoclonal antibody, DM1A (ab7291), against a-tubulin (Abcam). For the anti-GATA3 antibody, the blocking solution was 2% bovine serum albumin in PBS-0.1% Tween and the incubation was carried out o/n at 4 1C. 5% skimmed milk powder in PBS-0.1% Tween served as blocking solution for the a-tubulin antibody. Immunofluorescence against GATA3 was also carried out with the antibody, ab11964 (Abcam), in 2% bovine serum albumin. CD31 was detected using a rat anti-mouse antibody (MEC13.3) from Pharmingen (BD Pharmingen, Oakville, Canada) using 1% bovine serum albumin, 2% Goat serum in PBS-0.05% Tween as blocking solution. Dilutions of antibodies for immunofluorescence were as follows: GATA3, 1:100; CD31, 1:600; and green fluorescent protein; 1:1000. Ki67 staining was carried out at the core facility at the IRIC of University de Montreal, Montreal, Canada.
Microarray and Quantitative RT-PCR
Total RNA from orthotopic tumors were extracted using Trizol reagent (Invitrogen, Burlington, Canada) and purified with the Rneasy MinElute Cleanup kit (Qiagen, Mississauga, Canada). Microarrays analyses were carried out by the Genome Quebec Innovation Centre (Montreal, QC, Canada) using total RNA on the Illumina BeadChip platform (Illumina, San Diego, CA, USA). Data analysis was carried out using FlexArray software (http://genomequebec.mcgill.ca/ FlexArray/). Reverse transcriptions were done using SuperScript II (Invitrogen). All quantitative PCR reactions were carried out in a Lightcycler (Roche, Laval, Canada) using a capillary-specific mastermix (SYBR Green JumpStart Taq ReadyMix-Sigma). Primer sequences used for RT-PCR are detailed in Supplementary Table 5 . All reactions were carried out with an annealing temperature of 60 1C. b-glucuronidase was used as normalizing gene in all quantitative RT-PCR experiments (de Kok et al., 2005) .
Chromatin immunoprecipitation
See supplementary methods for protocol and primers.
Statistical analysis
All results are reported as mean þ /À s.e.m. unless otherwise noted. The t-tests, w 2 and survival curve analysis were carried out using Prism 3.0 (GraphPad Software, www.GraphPad. com). Statistical analysis of lung metastasis was carried out using log10 transformed raw photon flux data and analysed by a two-by-four repeated measures (MANOVA) analysis using SPSS 16.0 (SPSS Statistics, www.SPSS.com).
Abbreviation ER, estrogen receptor-a.
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